Adverum Biotechnologies, Inc. (0HA3.L)

11,22 +0,03 (+0,29%) Alla chiusura: 04:08PM BST

Adverum Biotechnologies, Inc.

100 Cardinal Way
Redwood City, CA 94063
United States
650 656 9323
https://adverum.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 121

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Laurent Fischer	President, CEO & Director	1,02M	N/D	1964
Ms. Linda M. Rubinstein M.A.	CFO, Principal Financial Officer & Principal Accounting Officer	940,99k	N/D	1967
Mr. Kishor Peter Soparkar J.D.	Chief Operating Officer	674,98k	N/D	1972
Dr. Setareh Seyedkazemi Pharm.D.	Chief Development Officer	656,84k	N/D	1975
Dr. R. Andrew Ramelmeier Ph.D.	Chief Technology Officer	N/D	N/D	1962
Dr. Romuald Corbau Ph.D.	Chief Scientific Officer	N/D	N/D	1969
Mr. John W. Rakow J.D.	Senior VP & General Counsel	954,24k	N/D	1957
Ms. Dena House	Chief People Officer	N/D	N/D	N/D
Ms. Carla Fiankan	Senior Vice President of Regulatory Affairs	N/D	N/D	N/D
Mr. Michael Steel	Senior Vice President of Quality	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Governance aziendale

L'ISS Governance QualityScore di Adverum Biotechnologies, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.